Päivi Hannuksela

Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors

R. Alemany, M. Cascalló, A. Hemminki, 2010, Clinical Cancer Research.

Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.

K. Partanen, A. Hemminki, K. Guse, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Integrin targeted oncolytic adenoviruses Ad5‐D24‐RGD and Ad5‐RGD‐D24‐GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors

K. Partanen, A. Hemminki, K. Guse, 2012, International journal of cancer.

Safety of glucocorticoids in cancer patients treated with oncolytic adenoviruses.

K. Partanen, A. Hemminki, V. Cerullo, 2011, Molecular pharmaceutics.

In vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments

A. Hemminki, V. Cerullo, A. Kanerva, 2011, Annals of medicine.